Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

The 22 most innovative biotech products of 2022

By Brian Buntz | August 15, 2022

Pharma 50 most innovative biotech products

Pharma 50 – most innovative biotech products

The Galien Foundation has rounded up its picks for the most innovative biotech products for its 2022 Prix Galien USA Awards, showcasing advances in biotechnology and health products.

The foundation does not include financial information in its nomination process. Consequently, its biotech roundup included few products that have reached blockbuster status.

The Galien Foundation will announce the final winners at a ceremony in New York City on October 27, 2022.

[Related: 34 of the most innovative pharmaceutical products] 

The following products are the Galien Foundation’s finalists for most innovative biotech products:

Company Biotech product Indications 2021 sales
Albireo Pharma, Inc. Bylvay (odevixibat) Pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis. $7,000,000.00
Alnylam Pharmaceuticals Givlaari (givosiran) Treatment of adults with acute hepatic porphyria. $128,000,000.00
Alnylam Pharmaceuticals Oxlumo (lumasiran) Primary hyperoxaluria type 1. $60,000,000.00
Amgen Inc. Evenity (romosozumab-aqqg) Osteoporosis in postmenopausal women at high risk for fracture. $101,000,000.00
argenx Vyvgart (efgartigimod alfa-fcab) Generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. $21,200,000.00
AstraZeneca and Daiichi Sankyo Enhertu (fam-trastuzumab – deruxtecan-nxki) Various breast cancers. Also, lung and gastric cancers. $214,000,000.00
BeiGene Brukinsa (zanubrutinib) Adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen. $218,000,000.00
Bristol Myers Squibb Abecma (idecabtagene vicleucel) Relapsed or refractory multiple myeloma after four or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. $164,000,000.00
ChemoCentryx Tavneos (avacopan) Severe active anti neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. $1,000,000.00
Genentech, a member of the Roche Group Polivy (polatuzumab vedotin-piiq) Relapsed or refractory diffuse large B-cell lymphoma. $234,304,200.00
GSK Blenrep (belantamab mafodotin-blmf) Relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. $109,274,200.00
Horizon Therapeutics Tepezza (teprotumumab-trbw) Thyroid eye disease. $1,660,000,000.00
Jazz Pharmaceuticals Rylaze (asparaginase erwinia chrysanthemi recombinant-rywn) Acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). $85,600,000.00
Merck & Co. Vaxneuvance (pneumococcal 15-valent conjugate vaccine) Immunization for the prevention of invasive disease caused by Streptococcus pneumoniae.
FDA approved Vaxneuvance in July 2021
Novartis Gene Therapies Zolgensma (onasemnogene abeparvovec-xioi) Spinal muscular atrophy (SMA) with bi-allelic mutations in the survival 135 motor neuron 1 (SMN1) gene. $469,000,000.00
Pfizer Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) Pneumonia and invasive disease caused by Streptococcus pneumoniae serotype. $5,272,000,000.00
Regeneron Pharmaceuticals Evkeeza (evinacumab-dgnb) Low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia. $18,400,000.00
Regeneron Pharmaceuticals Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Treatment of infection caused by Zaire ebola virus in adult and pediatric patients. No sales data available
Regeneron Pharmaceuticals and Sanofi Dupixent (dupilumab) Adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. $6,209,567,000.00
Sanofi Cablivi (caplacizumab-yhdp) Adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression. $168,428,000.00
VBI Vaccines Inc. PreHevbrio (Sci-B-Vac) Prevention of infection caused by all known subtypes of hepatitis B virus.
Approved by the FDA on November 30, 2021
XVIVO Perfusion XPS with STEEN Solution Flushing and temporary continuous normothermic machine perfusion. —

Filed Under: Biologics
Tagged With: Galien Foundation, most innovative biotech products
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Cellares and UW-Madison partner to automate manufacturing for novel solid tumor CAR-T
Avoiding aggregates: How new technology is helping mAb developers monitor a vital CQA
Eli Lilly in the Drug Discovery & Development Pharma 50
Lilly’s FDA approval for Omvoh close up: Nearly 90% of one-year responders maintained remission through two years
Lumen Bioscience
How an engineered algae-based biologic aims to break the annual $5B cycle of c. diff reinfection
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE